SUSTIVA

Compare SUSTIVA  to:
Compare
Compare

Generic Name for SUSTIVA

Efavirenz 50mg, 100mg, 200mg; caps.

Legal Classification:

Rx

Pharmacological Class for SUSTIVA

Non-nucleoside reverse transcriptase inhibitor.

Manufacturer of SUSTIVA

Bristol-Myers Squibb Virology

Indications for SUSTIVA

HIV-1 infection.

Adults and Children:

Give once daily on an empty stomach, preferably at bedtime. Consider pretreating with antihistamine (for children) or steroid to minimize rash. <3years: not recommended. ≥3years (10kg to <15kg): 200 mg; (15kg to <20kg): 250mg; (20kg to <25kg): 300mg; (25kg to <32.5kg): 350mg; (32.5kg to <40kg): 400mg; (≥40kg) and adults: 600mg.

Also:

Contraindications for SUSTIVA

Concomitant cisapride, ergots, midazolam, triazolam, voriconazole.

Precautions for SUSTIVA

CNS or psychiatric disturbances. Seizures. Hepatic dysfunction. Monitor cholesterol and triglycerides; monitor liver function in suspected or known history of hepatitis B or C. Discontinue if severe rash (w. blistering, desquamation, mucosal involvement, or fever) occurs. Obtain (–) pregnancy test before starting; use adequate (barrier + hormonal) contraception. Elderly. Pregnancy (Cat.D), nursing mothers: not recommended.

Interactions for SUSTIVA

See Contraindications. Avoid alcohol, other psychoactive and/or hepatotoxic drugs. Antagonized by St. John's wort: not recommended. Caution with drugs metabolized by, or that affect activity of, CYP2C9, CYP2C19, CYP3A4. Efavirenz levels decreased by phenobarbital, rifampin, rifabutin. May decrease levels of indinavir (increase indinavir to 1g every 8 hours), amprenavir, clarithromycin, methadone, rifabutin (increase dose: see literature). Efavirenz increases nelfinavir, ethinyl estradiol plasma levels. Levels of both drugs increased with ritonavir (monitor liver function and for adverse events). Levels of both drugs are decreased with saquinavir (do not use as sole protease inhibitor). Closely monitor warfarin, anticonvulsants (esp. phenytoin, phenobarbital, carbamazepine), rifabutin, others. May cause false (+) cannabis screening test (CEDIA DAU multi-level THC assay).

Adverse Reactions for SUSTIVA

CNS effects (eg, drowsiness, dizziness, insomnia, impaired concentration, abnormal dreams), psychiatric effects (eg, severe depression, suicidal ideation/attempt, aggression, paranoia, mania, delusions, psychosis), rash (may be severe; eg, Stevens-Johnson, erythema multiforme), GI upset, fever, cough, dyspnea, redistribution of body fat.

How is SUSTIVA supplied?

Caps 50mg, 100mg—30
200mg—90
Tabs 600mg—30

Related Disease:

HIV~antivirals

Related Resources

FDA reviews cardiac risk of Invirase in combination with Norvir

February 23, 2010

The FDA has notified healthcare professionals and patients that it is reviewing clinical trial data about a potentially serious effect on the heart associated with the use of Invirase (saquinavir, from Roche) in combination with Norvir (ritonavir, from Abbott).

Heat-stable Norvir tablets approved

February 16, 2010

The FDA has approved a heat-stable formulation of Norvir tablets (ritonavir, from Abbott) that can be stored at room temperature.

Videx and Videx EC labeling revised to include risk of non-cirrhotic portal hypertension

January 29, 2010

The FDA has notified healthcare professionals and patients that the use of Videx or Videx EC (didanosine, from Bristol-Myers Squibb) may cause non-cirrhotic portal hypertension, a rare but serious complication.

Prezista labeling updated to include 96-week data

January 28, 2010

Tibotec Therapeutics announced that the FDA has approved an updated label for Prezista (darunavir tablets) which includes 96-week data from the ARTEMIS and TITAN studies.

Exel/Exelint infusion set needles recalled

January 26, 2010

FDA notified healthcare professionals of a Class I recall of Exel/Exelint Huber needles, Exel/Exelint Huber Infusion Sets, and Exel/Exelint "Securetouch+" Safety Huber Infusion Sets due to 'coring,' the cutting or dislodging of silicone cores or slivers from the ports into which they are inserted).